ResMed (NYSE:RMD) CEO Sells $968,054.36 in Stock

June 10, 2026 by InsiderTrades.com

Key Points

ResMed CEO Michael Farrell sold 4,991 shares on June 8 in a pre-arranged Rule 10b5-1 transaction, generating about $968,054 and trimming his stake by 1.06%.
The company recently beat quarterly expectations, reporting EPS of $2.86 versus the $2.79 consensus and revenue of $1.43 billion, up 10.8% year over year.
ResMed remains a dividend payer and institutionally held stock, with a quarterly dividend of $0.60 per share and institutional investors owning about 54.98% of shares.

ResMed Inc. (NYSE:RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $193.96, for a total value of $968,054.36. Following the sale, the chief executive officer owned 466,256 shares in the company, valued at approximately $90,435,013.76. This represents a 1.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Trading Up 1.9%

HCA Healthcare Rallies: Weight-loss drugs really a big threat?

NYSE:RMD opened at $196.75 on Wednesday. The company has a market cap of $28.54 billion, a P/E ratio of 18.97, a P/E/G ratio of 1.23 and a beta of 0.80. The stock's fifty day moving average price is $212.06 and its two-hundred day moving average price is $236.44. ResMed Inc. has a 1 year low of $180.26 and a 1 year high of $293.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.42 billion. During the same quarter last year, the business posted $2.37 earnings per share. The firm's revenue was up 10.8% compared to the same quarter last year. As a group, analysts expect that ResMed Inc. will post 11.13 EPS for the current year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 14th. ResMed's dividend payout ratio (DPR) is 23.14%.

Institutional Investors Weigh In On ResMed

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in ResMed by 1.6% during the third quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider's stock valued at $5,211,940,000 after purchasing an additional 293,515 shares in the last quarter. State Street Corp raised its position in ResMed by 1.2% during the fourth quarter. State Street Corp now owns 6,625,408 shares of the medical equipment provider's stock valued at $1,595,862,000 after purchasing an additional 76,244 shares in the last quarter. Bank of New York Mellon Corp raised its position in ResMed by 0.7% during the first quarter. Bank of New York Mellon Corp now owns 4,925,386 shares of the medical equipment provider's stock valued at $1,105,651,000 after purchasing an additional 34,732 shares in the last quarter. Geode Capital Management LLC raised its position in ResMed by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 4,302,906 shares of the medical equipment provider's stock valued at $1,032,877,000 after purchasing an additional 51,218 shares in the last quarter. Finally, Morgan Stanley raised its position in ResMed by 25.0% during the fourth quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider's stock valued at $696,523,000 after purchasing an additional 578,559 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on RMD shares. Wall Street Zen downgraded ResMed from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Wells Fargo & Company lowered their price objective on ResMed from $270.00 to $227.00 and set an "equal weight" rating on the stock in a research report on Friday, May 1st. JPMorgan Chase & Co. started coverage on ResMed in a research report on Wednesday, April 15th. They issued an "overweight" rating on the stock. KeyCorp lowered their price objective on ResMed from $302.00 to $290.00 and set an "overweight" rating on the stock in a research report on Monday, April 27th. Finally, Robert W. Baird set a $225.00 price objective on ResMed in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, ResMed has an average rating of "Moderate Buy" and a consensus price target of $286.18.

View Our Latest Analysis on ResMed

About ResMed

(Get Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.